Epilepsy Drugs Market Analysis, Scope, and Growth by 2031
Epilepsy Drugs Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 7.7 Billion |
Market Size by 2030 | US$ 10.7 Billion |
Global CAGR (2022 - 2030) | 4.1% |
Historical Data | 2020-2021 |
Forecast period | 2022-2030 |
Segments Covered |
By Treatment
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Epilepsy Drugs Market News and Recent Developments
The Epilepsy Drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Epilepsy Drugs market are listed below:
- Eisai Co., Ltd. announced new product launch "Fycompa" intended for intravenous (IV) infusion. The injection formulation of Fycompa received manufacturing and marketing approval on January 2024 and this was included in the Japan's National Health Insurance (NHI) Drug Price list today. Fycompa is the first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. (Source: Eisai Co., Ltd, Press Release, April 2024)
Epilepsy Drugs Market Report Coverage and Deliverables
The “Epilepsy Drugs Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
- Epilepsy Drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Epilepsy Drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Epilepsy Drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Epilepsy Drugs market
- Detailed company profiles